FierceBiotech  Jul 27  Comment 
Eli Lilly says that it will push ahead to the end on its Phase III study of evacetrapib, a CETP inhibitor that hopes to succeed where other giants have failed.
newratings.com  Jul 27  Comment 
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) announced it has accepted the recommendation of the ACCELERATE study data monitoring committee to continue the Phase 3 trial of the investigational medicine evacetrapib, based on data from an...
Financial Times  Jul 24  Comment 
Credit Suisse’s strong results; Eli Lilly and Lockheed also in the news
Benzinga  Jul 23  Comment 
In separate reports published Thursday, Evercore-ISI's Biotechnology analyst Mark Schoenebaum dissected Eli Lilly and Co (NYSE: LLY) and Bristol-Myers Squibb Co (NYSE: BMY)'s conference call following the release of their quarterly results. Eli...
Benzinga  Jul 23  Comment 
Eli Lilly and Co (NYSE: LLY) came out with remarkable second-quarter numbers on Thursday. The company reported adjusted EPS of $0.90, beating consensus analysts' estimates of adjusted EPS of $0.74 by $0.16. John Lechleiter, Eli Lilly CEO, was on...
Wall Street Journal  Jul 23  Comment 
Drug maker Eli Lilly’s profit fell 18%, but its purchase of an animal-drug business helped squeeze out a quarterly revenue increase, and the company raised its 2015 outlook.
FierceBiotech  Jul 23  Comment 
Biotech's ongoing boom has inflated valuations for upstart drugmakers, and Eli Lilly CEO John Lechleiter said his company is wary of getting involved in any high-dollar bidding wars to bring in new treatments.
TheStreet.com  Jul 23  Comment 
NEW YORK (TheStreet) -- Eli Lilly shares are up by 3.13% to $89.08 at the start of trading on Thursday morning, after the company released its 2015 second quarter earnings results.The Indianapolis, IN-based pharmaceutical company reported...
FiercePharma  Jul 23  Comment 
Eli Lilly was standing at the bottom of a steep slope earlier this year, with slumping sales for older meds and a 2015 forecast that fell short of analysts' expectations. But CEO John Lechleiter predicted good things were ahead for the company,...


Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki